What to Expect From Celgene Corporation in 2018
After two years of lackluster performances, Celgene Corporation (NASDAQ: CELG) appeared to be on a roll in 2017. Then the bottom fell out.
In October, the big biotech stock gave up all of its year-to-date gains, and then some. A massive sell-off resulted from the late-stage clinical failure for GED-0301, and third-quarter headwinds for Otezla. What was once a promising year turned into another disappointment for Celgene shareholders.
Will Celgene have better luck next year? Here's what to expect from the biotech in 2018.
Source: Fool.com